Abicipar pegol

N/A

Report date: 2024/06/19 20:00:11

Base Information

Drug NameAbicipar pegol
Drug Alias Nameabicipar pegol培阿比西帕培戈-阿比西帕Anti-VEGF DARPinabiciparum pegolum +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Edema +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[32] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMolecular Partners Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAllergan PlcMolecular Partners Ag
Active IndicationsN/A
Inactive IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Edema +[4] 

Other Information

ATC CodeN/A
Related LinksN/A